SPYRE THERAPEUTICS INC

Spyre Therapeutics CFO buys 7,500 shares, signaling confidence ahead of Phase‑2 read‑outs for IBD candidates SPY001 and SPY002, while execs balance sell‑side activity.

Spyre Therapeutics CFO Scott Burrows’ recent buy‑sell‑buy pattern reveals a tactical, bullish stance on the biotech’s IBD pipeline, signaling insider confidence amid volatility.

Fairmount’s conversion of Spyre preferred shares into common stock signals strong institutional confidence, boosting stability while highlighting key clinical and reimbursement opportunities in precision immunology.

Spyre Therapeutics insider sale analysis: what Michael Henderson’s 20k‑share sale says about the company’s confidence, clinical progress, and future prospects.

Spyre Therapeutics insider trades reveal strategic confidence: a broad licensing deal with Paragon could unlock IBD market gains, boosting drug‑development prospects and market access.

Fairmount’s new option deal on Spyre Therapeutics signals confidence in its precision immunology pipeline, highlighting key trials, safety data, and potential upside.

Spyre Therapeutics CFO’s disciplined insider trades reveal confidence—buying at $14.50 vs. $69.42 market, signaling potential upside as IBD programs progress.

Spyre Therapeutics’ CEO’s 10b5‑1 stock sales show disciplined insider trading, reinforcing long‑term commitment while hinting at short‑term volatility ahead of key UC/CD clinical milestones.

Spyre CEO Turtle Cameron sells 15,000 shares at premium—insider liquidity strategy amid investor‑conference buzz.

Spyre Therapeutics’ new executive option grants signal confidence and long‑term commitment to its IBD antibody pipeline, highlighting potential upside and investor interest.